LeMaitre Vascular Q2 sales climb 10% as gross margin reaches 72.1%; FDA re-inspection concludes

summarizeSummary

LeMaitre Vascular posted Q2 2026 net sales of $70.4 million (+10% YoY) and EPS of $0.74, with gross margin improving to 72.1%. The FDA completed a re-inspection of its Artegraft facility, identifying new observations.

check_boxKey Events · Earnings and Guidance · LMAT

• Q2 Sales +10%, EPS $0.74

  Net sales reached $70.4 million, a 10% increase year-over-year, with diluted EPS of $0.74, up 23% from $0.60 in Q2 2025.

• Gross Margin Expands to 72.1%

  Gross margin improved 210 basis points to 72.1%, driven by price increases, favorable product mix, and lower shipping costs.

• FDA Re-Inspection Completed

  The FDA completed a re-inspection of the Artegraft facility in June 2026 and identified new inspectional observations. The company continues to address the August 2025 warning letter.

• $100M Buyback Authorized, Unused

  The board authorized a $100 million share repurchase program in February 2026, but no shares have been repurchased to date.

auto_awesomeAnalysis · LMAT · Industrial Applications And Services

A solid quarter for LeMaitre Vascular saw sales rise 10% to $70.4 million and net income advance 24% to $17.1 million. Gross margin expanded 210 basis points to 72.1%, helped by price increases and a favorable product mix. The balance sheet remains robust, with $376 million in cash and securities against $169 million in convertible notes. An FDA re-inspection of the Artegraft facility wrapped up in June 2026, though new observations were noted — a regulatory overhang that warrants monitoring. The board also authorized a $100 million share buyback, but no repurchases have been made yet.